nevirapine has been researched along with HIV in 140 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
Excerpt | Relevance | Reference |
---|---|---|
"HIV-infected, Zambian children were randomized to initiate antiretroviral therapy (ART) with full-dose twice-daily nevirapine versus 2-week nevirapine dose-escalation." | 9.17 | Is nevirapine dose-escalation appropriate in young, African, HIV-infected children? ( Burger, DM; Chintu, C; Cook, A; Fillekes, Q; Gibb, DM; Kabamba, D; Kankasa, C; Mulenga, V; Thomason, MJ; Walker, AS, 2013) |
"In a pharmacokinetic pilot trial (NCT01187719), HIV-infected, antiretroviral (ARV)-naive pregnant women ≥18 years old from Zambia and Tanzania and with CD4 cell counts >350 cells/mm(3) were randomized 1 : 1 to a control (zidovudine pre-delivery, single-dose nevirapine/zidovudine/lamivudine at delivery and zidovudine/lamivudine for 7 days post-delivery) or an intervention (control plus 184 mg of phenytoin once daily for 7 days post-delivery) group." | 9.17 | Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ( Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013) |
"Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV)." | 9.17 | Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. ( Bonhomme, J; Chan, ES; Halvas, EK; Hitti, J; Hong, F; Hughes, MD; Kabanda, J; Klingman, KL; Kumarasamy, N; McMahon, DK; Mellors, JW; Taulo, F; Wallis, CL; Zheng, L, 2013) |
"Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy." | 9.16 | A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. ( Achalapong, J; Beck, IA; Britto, P; Chotivanich, N; Cressey, TR; Frenkel, L; Jourdain, G; Maupin, R; Mirochnick, M; Ngo-Giang-Huong, N; Prommas, S; Puthanakit, T; Rasri, W; Roongpisuthipong, A; Shapiro, DE; Van Dyke, RB; Yuthavisuthi, P, 2012) |
" We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children." | 9.15 | Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ( Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011) |
"Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission." | 9.14 | Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. ( Balasubramaniam, U; Bharadwaj, R; Bhore, AV; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kagal, A; Kulkarni, S; Kulkarni, V; Moorthy, A; Patil, S; Persaud, D; Sastry, J; Suryavanshi, N; Thakar, M; Tripathy, S; Venkataramani, V; Ziemniak, C, 2009) |
"The aim of this study was to evaluate the pharmacokinetics of lamivudine (3TC), stavudine (d4T) and nevirapine (NVP) in HIV-infected Malawian children receiving quartered tablet multiples of Triomune 40 (generic tablet [GT]) compared with individual generic liquid (GL) and trade liquid (TL)." | 9.14 | Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. ( Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R, 2010) |
"The purpose of this study was to evaluate the efficacy and safety of three nevirapine-based antiretroviral treatments for adult antiretroviral-naïve Chinese patients with HIV-1 infection." | 9.13 | Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. ( Dai, Y; Han, Y; Jiang, J; Kuang, J; Li, T; Li, Y; Qiu, Z; Xie, J; Zuo, L, 2008) |
"To examine the effect of 2 weeks of treatment with prednisone on the incidence of nevirapine-associated rash in HIV-1-infected patients receiving combination antiretroviral therapy." | 9.10 | Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003) |
"Nevirapine has an exceptional record for long-term tolerability with few side effects in human immunodeficiency virus (HIV) combined antiretroviral therapy (cART)." | 7.91 | Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management? ( Bregenzer, A; Kahlert, CR; Notter, J; Vernazza, P, 2019) |
"The objective of this study was to determine the prevalence of drug resistance mutations among HIV-positive women in Malawi 18 months after discontinuing nevirapine-based ART for the prevention of mother-to-child transmission." | 7.81 | Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Vella, S, 2015) |
"Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 7.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
"We modeled nevirapine (NVP) pharmacokinetics in HIV-infected Malawian patients to assess the relationship between drug exposure and patient characteristics, genetic polymorphisms, and development of hypersensitivity reaction (HSR)." | 7.80 | Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. ( Carr, DF; Chaponda, M; Dickinson, L; Heyderman, RS; Khoo, SH; Kumwenda, J; Lalloo, DG; Pirmohamed, M; van Oosterhout, JJ, 2014) |
"Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity." | 7.80 | HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014) |
" The interaction of the NNRTI nevirapine (NVP) with HIV-1 reverse transcriptase (RT) is characterized by a preference for the open conformation of the fingers/thumb subdomains, and a reported variation of three orders of magnitude between the binding affinity of NVP for RT in the presence or absence of primer/template DNA." | 7.79 | Protein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP. ( DeRose, EF; London, RE; Mueller, GA; Zheng, X, 2013) |
"This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment." | 7.76 | Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. ( Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010) |
"Seventy HIV-infected patients receiving rifampin for active TB (TB group) and 70 HIV-mono-infected patients (control group) were enrolled to receive nevirapine 400mg/day-based ART." | 7.76 | Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. ( Chimsuntorn, S; Eampokarap, B; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Tantanathip, P; Thongyen, S, 2010) |
"Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis." | 7.75 | In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. ( Bagenda, D; Bakaki, P; Church, JD; Donnell, D; Eshleman, SH; Eure, C; Fowler, MG; Guay, LA; Jackson, JB; Matovu, F; McConnell, M; Musoke, P; Mwatha, A; Nakabiito, C; Omer, SB; Thigpen, MC, 2009) |
"Single-dose nevirapine (SDNVP) for the prevention of mother-to-child HIV transmission (PMTCT) results in the selection of resistance mutants among HIV-infected mothers." | 7.74 | Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. ( Aldrovandi, GM; Kankasa, C; Kuhn, L; Semrau, K; Sinkala, M; Thea, DM; Walter, J, 2008) |
"Single-dose nevirapine (SD NVP) at birth plus NVP prophylaxis for the infant up to 6 weeks of age is superior to SD NVP alone for prevention of vertical transmission of human immunodeficiency virus (HIV) through breastfeeding." | 7.74 | Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. ( Church, JD; Eshleman, SH; Guay, LA; Huang, W; Jackson, JB; Lidstrom, J; Mmiro, F; Musoke, P; Omer, SB, 2008) |
"Single-dose nevirapine (SDNVP) is widely used to prevent mother-to-child HIV transmission in resource-limited settings." | 7.74 | Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. ( Bagenda, D; Bakaki, P; Downing, R; Eure, C; Fowler, MG; Greenberg, AE; Matovu, F; McConnell, M; Mubiru, M; Thigpen, MC, 2007) |
"The influence of nevirapine, efavirenz and tenofovir co-administration on ritonavir-boosted atazanavir pharmacokinetics was investigated in HIV (human immunodeficiency virus)-infected patients." | 7.73 | Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. ( Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O, 2006) |
"Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate." | 6.43 | In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). ( Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P, 2005) |
"The clinical significance of the reduced in vitro susceptibility of HIV to antiretroviral agents has been difficult to elucidate for nucleoside analogs such as zidovudine." | 6.17 | Resistance, drug failure, and disease progression. ( Richman, DD, 1994) |
"Nevirapine has been used as antiretroviral agent since early '90." | 5.48 | Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. ( Cattaneo, D; Cheli, S; Clementi, E; Di Cristo, V; Falvella, FS; Galli, M; Giacomelli, A; Lupo, A; Oreni, ML; Renisi, G; Ridolfo, AL; Riva, A; Rusconi, S, 2018) |
"HIV-infected, Zambian children were randomized to initiate antiretroviral therapy (ART) with full-dose twice-daily nevirapine versus 2-week nevirapine dose-escalation." | 5.17 | Is nevirapine dose-escalation appropriate in young, African, HIV-infected children? ( Burger, DM; Chintu, C; Cook, A; Fillekes, Q; Gibb, DM; Kabamba, D; Kankasa, C; Mulenga, V; Thomason, MJ; Walker, AS, 2013) |
"030 mg ethinyl estradiol with either nevirapine (NVP) or efavirenz (EFV) in 34 HIV-positive women." | 5.17 | Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. ( Ahluwalia, J; Ananworanich, J; Chaithongwongwatthana, S; Gorowara, M; Kriengsinyot, R; Landolt, NK; Lange, JM; Phanuphak, N; Pinyakorn, S; Thammajaruk, N; Thongpaeng, P; Ubolyam, S, 2013) |
"Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV)." | 5.17 | Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. ( Bonhomme, J; Chan, ES; Halvas, EK; Hitti, J; Hong, F; Hughes, MD; Kabanda, J; Klingman, KL; Kumarasamy, N; McMahon, DK; Mellors, JW; Taulo, F; Wallis, CL; Zheng, L, 2013) |
"In a pharmacokinetic pilot trial (NCT01187719), HIV-infected, antiretroviral (ARV)-naive pregnant women ≥18 years old from Zambia and Tanzania and with CD4 cell counts >350 cells/mm(3) were randomized 1 : 1 to a control (zidovudine pre-delivery, single-dose nevirapine/zidovudine/lamivudine at delivery and zidovudine/lamivudine for 7 days post-delivery) or an intervention (control plus 184 mg of phenytoin once daily for 7 days post-delivery) group." | 5.17 | Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ( Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013) |
"Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy." | 5.16 | A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. ( Achalapong, J; Beck, IA; Britto, P; Chotivanich, N; Cressey, TR; Frenkel, L; Jourdain, G; Maupin, R; Mirochnick, M; Ngo-Giang-Huong, N; Prommas, S; Puthanakit, T; Rasri, W; Roongpisuthipong, A; Shapiro, DE; Van Dyke, RB; Yuthavisuthi, P, 2012) |
"From the French Hospital Database on HIV, we selected 439 patients with undetectable viral load (VL) on a first-line boosted PI-containing cART regimen who switched to a PI-free combination including efavirenz, nevirapine or abacavir." | 5.15 | Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. ( Abgrall, S; Bommenel, T; Costagliola, D; Gilquin, J; Katlama, C; Lascaux, AS; Launay, O; Mahamat, A; Martinez, V; Meynard, JL; Pradier, C; Rouveix, E; Simon, A, 2011) |
" We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children." | 5.15 | Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ( Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011) |
"For almost a decade, single-dose nevirapine (sdNVP) has been proven to be a safe and effective drug for the prevention of mother-to-child transmission (PMTCT) of HIV." | 5.14 | Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia. ( Bweupe, M; Dirks, R; Kabaso, M; Kasonde, P; Mandala, J; Sangiwa, G; Torpey, K, 2010) |
"Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission." | 5.14 | Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. ( Balasubramaniam, U; Bharadwaj, R; Bhore, AV; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kagal, A; Kulkarni, S; Kulkarni, V; Moorthy, A; Patil, S; Persaud, D; Sastry, J; Suryavanshi, N; Thakar, M; Tripathy, S; Venkataramani, V; Ziemniak, C, 2009) |
"The aim of this study was to evaluate the pharmacokinetics of lamivudine (3TC), stavudine (d4T) and nevirapine (NVP) in HIV-infected Malawian children receiving quartered tablet multiples of Triomune 40 (generic tablet [GT]) compared with individual generic liquid (GL) and trade liquid (TL)." | 5.14 | Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. ( Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R, 2010) |
"The purpose of this study was to evaluate the efficacy and safety of three nevirapine-based antiretroviral treatments for adult antiretroviral-naïve Chinese patients with HIV-1 infection." | 5.13 | Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. ( Dai, Y; Han, Y; Jiang, J; Kuang, J; Li, T; Li, Y; Qiu, Z; Xie, J; Zuo, L, 2008) |
"To examine the effect of 2 weeks of treatment with prednisone on the incidence of nevirapine-associated rash in HIV-1-infected patients receiving combination antiretroviral therapy." | 5.10 | Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003) |
" In a prospective study of 31 HIV-infected patients included in a salvage regimen with stavudine, nevirapine, nelfinavir, and saquinavir, viral load decreased a median of 1." | 5.09 | Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. ( Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R, 2001) |
"Treatment of human immunodeficiency virus (HIV) infection with nevirapine in patients with < 400 CD4 cells/mm3 rapidly selects for virus with reduced susceptibility to nevirapine." | 5.08 | A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of > 500/mm3: AIDS Clinical Trials Group Protocol 208. ( Havlir, D; McLaughlin, MM; Richman, DD, 1995) |
"Maternal HIV drug resistance and maternal viral load were independent risk factors for vertical transmission during breastfeeding, suggesting that nevirapine alone may be insufficient infant prophylaxis against drug-resistant variants in maternal breast milk." | 4.12 | Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants. ( Beck, IA; Boyce, CL; DeMarrais, P; Flynn, PM; Fowler, MG; Frenkel, LM; Ko, D; Owor, M; Sils, T; Stranix-Chibanda, L; Styrchak, SM; Taha, TE; Tierney, C; Wong-On-Wing, A, 2022) |
" Younger age, male sex, less education, suboptimal adherence, receiving nevirapine, HIV non-disclosure, never having married and residing in Zimbabwe, Lesotho or Zambia were associated with higher odds of NVL." | 3.96 | Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys. ( Ao, TT; Barradas, DT; Bello, G; Birhanu, S; Brown, K; Frederix, K; Haas, AD; Hakim, AJ; Jahn, A; Jonnalagadda, S; Justman, JE; Kalua, T; Kim, E; Low, A; Mugurungi, O; Mulenga, LB; Musuka, G; Parekh, B; Patel, H; Philip, NM; Radin, E; Rogers, JH; Sachathep, K; Saito, S; Schwitters, AM; Sleeman, K; Thin, K; Tippett Barr, BA; Voetsch, AC; Williams, DB, 2020) |
"Nevirapine has an exceptional record for long-term tolerability with few side effects in human immunodeficiency virus (HIV) combined antiretroviral therapy (cART)." | 3.91 | Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management? ( Bregenzer, A; Kahlert, CR; Notter, J; Vernazza, P, 2019) |
"Despite improved policies to prevent mother-to-child HIV transmission (MTCT), adherence to maternal antiretroviral therapy (ART) and infant Nevirapine prophylaxis (NVP) is low in South Africa." | 3.91 | Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa. ( Ayalew, K; Cheyip, M; Chirinda, W; Dinh, TH; Goga, A; Jackson, D; Kindra, G; Larsen, A; Lombard, C; Magasana, V; Ngandu, N, 2019) |
"Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 3.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
"The objective of this study was to determine the prevalence of drug resistance mutations among HIV-positive women in Malawi 18 months after discontinuing nevirapine-based ART for the prevention of mother-to-child transmission." | 3.81 | Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Vella, S, 2015) |
" The present work envisages the development of a stealth anti-CD4 conjugated immunoliposomes containing two anti-retroviral drugs (nevirapine and saquinavir) that can selectively home into HIV infected cells through the CD4 receptor." | 3.81 | Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV. ( Krishnan, UM; Ramana, LN; Ranga, U; Sethuraman, S; Sharma, S, 2015) |
"We modeled nevirapine (NVP) pharmacokinetics in HIV-infected Malawian patients to assess the relationship between drug exposure and patient characteristics, genetic polymorphisms, and development of hypersensitivity reaction (HSR)." | 3.80 | Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. ( Carr, DF; Chaponda, M; Dickinson, L; Heyderman, RS; Khoo, SH; Kumwenda, J; Lalloo, DG; Pirmohamed, M; van Oosterhout, JJ, 2014) |
"Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity." | 3.80 | HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014) |
"Nevirapine resistance after failed prophylaxis to prevent mother-to-child human immunodeficiency virus (HIV) transmission can compromise subsequent nevirapine-based highly active antiretroviral therapy (HAART)." | 3.77 | Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. ( Abrams, EJ; Chen, YH; Coovadia, A; Kuhn, L; Meyers, T; Moorthy, A; Persaud, D; Sherman, G; Strehlau, R; Tsai, WY, 2011) |
"To evaluate the effect of a previous single dose of nevirapine given to prevent mother-to-child transmission of human immunodeficiency virus (HIV) on virologic and immunologic measures after months of an antiretroviral regimen containing either efavirenz or lopinavir-ritonavir." | 3.77 | Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir. ( Dewar, RL; Dlamini, JN; Follmann, DA; Highbarger, HC; Hu, Z; Pau, AK; Somaroo, H, 2011) |
"Compare the risk of HIV drug resistance in women stopping suppressive nelfinavir (NFV)-based or Nevirapine (NVP)-based antiretroviral therapy (ART) after pregnancy." | 3.77 | Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum. ( Ellis, GM; Frenkel, LM; Hitti, J; Huang, S, 2011) |
"Seventy HIV-infected patients receiving rifampin for active TB (TB group) and 70 HIV-mono-infected patients (control group) were enrolled to receive nevirapine 400mg/day-based ART." | 3.76 | Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. ( Chimsuntorn, S; Eampokarap, B; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Tantanathip, P; Thongyen, S, 2010) |
"This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment." | 3.76 | Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. ( Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010) |
"Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis." | 3.75 | In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. ( Bagenda, D; Bakaki, P; Church, JD; Donnell, D; Eshleman, SH; Eure, C; Fowler, MG; Guay, LA; Jackson, JB; Matovu, F; McConnell, M; Musoke, P; Mwatha, A; Nakabiito, C; Omer, SB; Thigpen, MC, 2009) |
"Single-dose nevirapine (SDNVP) for the prevention of mother-to-child HIV transmission (PMTCT) results in the selection of resistance mutants among HIV-infected mothers." | 3.74 | Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. ( Aldrovandi, GM; Kankasa, C; Kuhn, L; Semrau, K; Sinkala, M; Thea, DM; Walter, J, 2008) |
"Single-dose nevirapine (SD NVP) at birth plus NVP prophylaxis for the infant up to 6 weeks of age is superior to SD NVP alone for prevention of vertical transmission of human immunodeficiency virus (HIV) through breastfeeding." | 3.74 | Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. ( Church, JD; Eshleman, SH; Guay, LA; Huang, W; Jackson, JB; Lidstrom, J; Mmiro, F; Musoke, P; Omer, SB, 2008) |
"Single-dose nevirapine (SDNVP) is widely used to prevent mother-to-child HIV transmission in resource-limited settings." | 3.74 | Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. ( Bagenda, D; Bakaki, P; Downing, R; Eure, C; Fowler, MG; Greenberg, AE; Matovu, F; McConnell, M; Mubiru, M; Thigpen, MC, 2007) |
" 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine (4'-Ed4T), a novel thymidine analog, has potent anti-human immunodeficiency virus (HIV) activity, maintains considerable activity against multidrug-resistant HIV strains, and is less inhibitory to mitochondrial DNA synthesis in cell culture than its progenitor stavudine (D4T)." | 3.74 | Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog. ( Baba, M; Cheng, YC; Dutschman, GE; Grill, SP; Hu, R; Lam, W; Paintsil, E; Tanaka, H, 2007) |
"The influence of nevirapine, efavirenz and tenofovir co-administration on ritonavir-boosted atazanavir pharmacokinetics was investigated in HIV (human immunodeficiency virus)-infected patients." | 3.73 | Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. ( Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O, 2006) |
"Combinations of the human immunodeficiency virus (HIV) Tat protein antagonist Ro 24-7429 with either the HIV protease inhibitor Ro 31-8959 or the HIV reverse transcriptase inhibitors AZT (3'-azido-3'-deoxythymidine), ddC (2',3'-dideoxycytidine), ddI (2',3'-dideoxyinosine), and nevirapine were synergistic or additive in reducing HIV type 1 p24 antigen production in CEM cells or inhibiting HIV type 1-induced syncytium formation in HT4-6C cells." | 3.69 | Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor. ( Connell, EV; Hsu, MC; Richman, DD, 1994) |
"We have investigated viral breakthrough during a long-term culture of HIV-1-infected cells with the non-nucleoside reverse transcriptase inhibitors (NNRTIs) 6-benzyl-1-ethoxymethyl-5-isopropyluracil (MKC-442), nevirapine and loviride (alpha-APA)." | 3.69 | Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells. ( Baba, M; Makino, M; Nakade, K; Okamoto, M; Yamada, K; Yuasa, S, 1996) |
"The nonnucleoside reverse transcriptase inhibitor nevirapine rapidly selects for mutant human immunodeficiency virus (HIV) in vivo." | 3.69 | Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. ( Eastman, S; Gamst, A; Havlir, DV; Richman, DD, 1996) |
" As of September 1, 1996, ADAP began covering HIV protease inhibitors, viral load evaluations, and other crucial anti-HIV and opportunistic infection agents, including nevirapine for HIV, cidofovir for CMV, and DaunoXome for Kaposi's sarcoma." | 3.69 | New York ADAP to cover new AIDS drugs plus viral load testing. ( Link, D, 1996) |
"This home-based HIV-care strategy is as effective as is a clinic-based strategy, and therefore could enable improved and equitable access to HIV treatment, especially in areas with poor infrastructure and access to clinic care." | 2.74 | Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. ( Amuron, B; Birungi, J; Bunnell, R; Coutinho, A; Foster, S; Grosskurth, H; Jaffar, S; Kyomuhangi, R; Levin, J; Mermin, J; Nabiryo, C; Namara, G; Ndembi, N; Opio, A; Tappero, JW, 2009) |
" Adjusting dosage by means of therapeutic drug monitoring would appear to be a reasonable way of maximising patient benefit from treatment." | 2.71 | Follow-up measurements of Nevirapine plasma levels over a prolonged period. ( Ebigbo, A; Klinker, H; Knipper, A; Langmann, P; Sienz, M; Winzer, R; Zilly, M, 2004) |
"The study was conducted among 42 adult AIDS Clinical Trials Group sites and 7 National Hemophilia Foundation centers." | 2.69 | A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T ( Balfour, HH; Erice, A; Fischl, MA; Henry, K; Hirsch, MS; Kahn, JO; Kenton, A; Kmack, A; Liou, SH; Martinez, A; Phair, J; Tierney, C, 1998) |
"Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate." | 2.43 | In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). ( Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P, 2005) |
"Nevirapine has been used as antiretroviral agent since early '90." | 1.48 | Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. ( Cattaneo, D; Cheli, S; Clementi, E; Di Cristo, V; Falvella, FS; Galli, M; Giacomelli, A; Lupo, A; Oreni, ML; Renisi, G; Ridolfo, AL; Riva, A; Rusconi, S, 2018) |
"Patients in the TREAT Asia HIV Observational Database receiving first-line ART for ≥ 6 months were included." | 1.40 | Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database. ( Boettiger, DC; Chaiwarith, R; Choi, JY; Ditangco, R; Kamarulzaman, A; Kantipong, P; Kerr, S; Kiertiburanakul, S; Kumarasamy, N; Law, M; Lee, C; Li, CK; Merati, TP; Mustafa, M; Ng, OT; Oka, S; Pham, TT; Pujari, S; Ratanasuwan, W; Sohn, A; Van Kinh, N; Vonthanak, S; Wong, WW; Yunihastuti, E; Zhang, F, 2014) |
"The surrogate markers of HIV/AIDS progression include CD4 T cell count and plasma viral load." | 1.40 | MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy. ( Holla, P; Jameel, S; Munshi, SU; Panda, H; Rewari, BB, 2014) |
"Eight patients who were infected with human immunodeficiency virus, and who had each sustained an adverse drug reaction while following a regimen including nevirapine, were switched to a regimen including efavirenz." | 1.31 | The tolerability of efavirenz after nevirapine-related adverse events. ( Barry, M; Clarke, S; Harrington, P; Mulcahy, F, 2000) |
" Good oral bioavailability was observed in rhesus monkeys upon oral dosing of 1 as a suspension in methocel." | 1.29 | 5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. ( Balani, SK; Ciccarone, TM; Condra, JH; Emini, EA; Goldman, ME; Greenlee, WJ; Kauffman, LR; MacTough, SC; Rooney, CS; Williams, TM, 1993) |
"When nevirapine was combined with zidovudine (AZT) and didanosine (ddI), patients' CD4 counts rose significantly and viral load was reduced to below detectable levels." | 1.29 | FDA approves first new class of HIV drugs. Food and Drug Administration. ( , 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 27 (19.29) | 18.2507 |
2000's | 41 (29.29) | 29.6817 |
2010's | 63 (45.00) | 24.3611 |
2020's | 9 (6.43) | 2.80 |
Authors | Studies |
---|---|
Williams, TM | 1 |
Ciccarone, TM | 1 |
MacTough, SC | 1 |
Rooney, CS | 1 |
Balani, SK | 1 |
Condra, JH | 1 |
Emini, EA | 1 |
Goldman, ME | 1 |
Greenlee, WJ | 1 |
Kauffman, LR | 1 |
Janssen, PA | 1 |
Lewi, PJ | 1 |
Arnold, E | 1 |
Daeyaert, F | 1 |
de Jonge, M | 1 |
Heeres, J | 1 |
Koymans, L | 1 |
Vinkers, M | 1 |
Guillemont, J | 2 |
Pasquier, E | 1 |
Kukla, M | 1 |
Ludovici, D | 1 |
Andries, K | 2 |
de Béthune, MP | 2 |
Pauwels, R | 1 |
Das, K | 1 |
Clark, AD | 1 |
Frenkel, YV | 1 |
Hughes, SH | 1 |
Medaer, B | 1 |
De Knaep, F | 1 |
Bohets, H | 1 |
De Clerck, F | 1 |
Lampo, A | 1 |
Williams, P | 1 |
Stoffels, P | 1 |
Paintsil, E | 1 |
Dutschman, GE | 1 |
Hu, R | 1 |
Grill, SP | 1 |
Lam, W | 1 |
Baba, M | 2 |
Tanaka, H | 1 |
Cheng, YC | 1 |
Massari, S | 2 |
Daelemans, D | 2 |
Manfroni, G | 2 |
Sabatini, S | 1 |
Tabarrini, O | 2 |
Pannecouque, C | 6 |
Cecchetti, V | 2 |
Le Van, K | 1 |
Cauvin, C | 1 |
de Walque, S | 1 |
Georges, B | 1 |
Boland, S | 1 |
Martinelli, V | 1 |
Demonté, D | 1 |
Durant, F | 1 |
Hevesi, L | 1 |
Van Lint, C | 1 |
Benjahad, A | 1 |
Oumouch, S | 1 |
Decrane, L | 1 |
Palandjian, P | 1 |
Vernier, D | 1 |
Queguiner, L | 1 |
Hertogs, K | 2 |
Grierson, DS | 1 |
Nguyen, CH | 1 |
Asaftei, S | 1 |
De Clercq, E | 3 |
Casano, G | 1 |
Dumètre, A | 1 |
Hutter, S | 1 |
Azas, N | 1 |
Robin, M | 1 |
Banerjee, D | 1 |
Yogeeswari, P | 1 |
Bhat, P | 1 |
Thomas, A | 1 |
Srividya, M | 1 |
Sriram, D | 1 |
Garnsey, MR | 1 |
Matous, JA | 1 |
Kwiek, JJ | 1 |
Coltart, DM | 1 |
Tian, Y | 1 |
Du, D | 1 |
Rai, D | 1 |
Wang, L | 1 |
Liu, H | 1 |
Zhan, P | 2 |
Liu, X | 2 |
Sancineto, L | 1 |
Iraci, N | 1 |
Barreca, ML | 1 |
Corazza, G | 1 |
Marcello, A | 1 |
Müller, R | 1 |
Mulani, I | 1 |
Basson, AE | 2 |
Pribut, N | 2 |
Hassam, M | 1 |
Morris, L | 2 |
van Otterlo, WAL | 1 |
Pelly, SC | 2 |
Pardo-Vargas, A | 1 |
Ramos, FA | 1 |
Cirne-Santos, CC | 1 |
Stephens, PR | 1 |
Paixão, ICP | 1 |
Teixeira, VL | 1 |
Castellanos, L | 1 |
Bala, V | 1 |
Jangir, S | 1 |
Mandalapu, D | 1 |
Gupta, S | 1 |
Chhonker, YS | 1 |
Lal, N | 1 |
Kushwaha, B | 1 |
Chandasana, H | 1 |
Krishna, S | 1 |
Rawat, K | 1 |
Maikhuri, JP | 1 |
Bhatta, RS | 1 |
Siddiqi, MI | 1 |
Tripathi, R | 1 |
Gupta, G | 1 |
Sharma, VL | 1 |
Patel, RV | 1 |
Park, SW | 1 |
Peet, J | 1 |
Selyutina, A | 1 |
Bredihhin, A | 1 |
Veale, CG | 1 |
van Otterlo, WA | 1 |
Elgaher, WA | 1 |
Sharma, KK | 1 |
Haupenthal, J | 1 |
Saladini, F | 1 |
Pires, M | 1 |
Real, E | 1 |
Mély, Y | 1 |
Hartmann, RW | 1 |
Xiao, T | 1 |
Tang, JF | 1 |
Meng, G | 1 |
Zhu, YY | 1 |
Liu, GY | 1 |
Xu, ZQ | 1 |
Wu, FS | 1 |
Gu, SX | 1 |
Chen, FE | 1 |
Gao, P | 1 |
Song, S | 1 |
Wang, Z | 2 |
Sun, L | 1 |
Zhang, J | 1 |
Boyce, CL | 1 |
Sils, T | 1 |
Ko, D | 1 |
Wong-On-Wing, A | 1 |
Beck, IA | 2 |
Styrchak, SM | 1 |
DeMarrais, P | 1 |
Tierney, C | 2 |
Stranix-Chibanda, L | 1 |
Flynn, PM | 1 |
Taha, TE | 1 |
Owor, M | 1 |
Fowler, MG | 3 |
Frenkel, LM | 2 |
Chua, KY | 1 |
Tey, KE | 1 |
Larsen, A | 1 |
Magasana, V | 1 |
Dinh, TH | 1 |
Ngandu, N | 1 |
Lombard, C | 2 |
Cheyip, M | 1 |
Ayalew, K | 1 |
Chirinda, W | 1 |
Kindra, G | 1 |
Jackson, D | 1 |
Goga, A | 1 |
Abdullahi, ST | 1 |
Soyinka, JO | 1 |
Olagunju, A | 1 |
Bolarinwa, RA | 1 |
Olarewaju, OJ | 1 |
Bakare-Odunola, MT | 1 |
Winterberg, M | 1 |
Tarning, J | 1 |
Owen, A | 1 |
Khoo, S | 1 |
Haas, AD | 1 |
Radin, E | 1 |
Hakim, AJ | 1 |
Jahn, A | 1 |
Philip, NM | 1 |
Jonnalagadda, S | 1 |
Saito, S | 1 |
Low, A | 1 |
Patel, H | 1 |
Schwitters, AM | 1 |
Rogers, JH | 1 |
Frederix, K | 1 |
Kim, E | 1 |
Bello, G | 1 |
Williams, DB | 1 |
Parekh, B | 1 |
Sachathep, K | 1 |
Barradas, DT | 1 |
Kalua, T | 1 |
Birhanu, S | 1 |
Musuka, G | 1 |
Mugurungi, O | 1 |
Tippett Barr, BA | 1 |
Sleeman, K | 1 |
Mulenga, LB | 1 |
Thin, K | 1 |
Ao, TT | 1 |
Brown, K | 1 |
Voetsch, AC | 1 |
Justman, JE | 1 |
Yang, H | 1 |
Chu, L | 1 |
Wu, Y | 2 |
Wang, W | 1 |
Yang, J | 1 |
Zhang, Q | 1 |
Qiao, S | 1 |
Li, X | 1 |
Shen, Z | 1 |
Zhou, Y | 1 |
Liu, S | 1 |
Deng, H | 1 |
Afrane, AKA | 1 |
Goka, BQ | 1 |
Renner, L | 1 |
Yawson, AE | 1 |
Alhassan, Y | 1 |
Owiafe, SN | 1 |
Agyeman, S | 1 |
Sagoe, KWC | 1 |
Kwara, A | 1 |
Prasertvit, P | 1 |
Chareonyingwattana, A | 1 |
Wattanakrai, P | 1 |
Van de Wijer, L | 1 |
Kinabo, GD | 1 |
Mchaile, DN | 1 |
de Mast, Q | 1 |
Schellekens, AFA | 1 |
van der Ven, AJAM | 1 |
Murnane, PM | 1 |
Strehlau, R | 2 |
Shiau, S | 1 |
Patel, F | 1 |
Mbete, N | 1 |
Hunt, G | 1 |
Abrams, EJ | 2 |
Coovadia, A | 2 |
Kuhn, L | 3 |
Su, S | 1 |
Fairley, CK | 1 |
Sasadeusz, J | 1 |
He, J | 1 |
Wei, X | 1 |
Zeng, H | 1 |
Jing, J | 1 |
Mao, L | 1 |
Chen, X | 1 |
Zhang, L | 1 |
Vaz, P | 1 |
Buck, WC | 1 |
Bhatt, N | 1 |
Bila, D | 1 |
Auld, A | 1 |
Houston, J | 1 |
Cossa, L | 1 |
Alfredo, C | 1 |
Jobarteh, K | 1 |
Sabatier, J | 1 |
Macassa, E | 1 |
Sousa, A | 1 |
DeVos, J | 1 |
Jani, I | 1 |
Yang, C | 1 |
Giacomelli, A | 1 |
Riva, A | 1 |
Falvella, FS | 1 |
Oreni, ML | 1 |
Cattaneo, D | 1 |
Cheli, S | 1 |
Renisi, G | 1 |
Di Cristo, V | 1 |
Lupo, A | 1 |
Clementi, E | 1 |
Rusconi, S | 1 |
Galli, M | 1 |
Ridolfo, AL | 1 |
Wang, X | 1 |
Guo, G | 1 |
Zheng, J | 1 |
Lu, L | 1 |
Ji, S | 1 |
Xu, Y | 1 |
Han, D | 1 |
Peng, X | 1 |
Lu, X | 1 |
Brockmeyer, NH | 1 |
Wu, N | 1 |
Potty, RS | 1 |
Sinha, A | 1 |
Sethumadhavan, R | 1 |
Isac, S | 1 |
Washington, R | 1 |
Notter, J | 1 |
Bregenzer, A | 1 |
Vernazza, P | 1 |
Kahlert, CR | 1 |
Apangu, P | 1 |
Izudi, J | 1 |
Bajunirwe, F | 1 |
Mulogo, E | 1 |
Batwala, V | 1 |
Mazanderani, AH | 1 |
Murray, TY | 1 |
Sherman, GG | 1 |
Snyman, T | 1 |
George, J | 1 |
Avenant, T | 1 |
Goga, AE | 2 |
Pepper, MS | 1 |
du Plessis, N | 1 |
Kiage, JN | 1 |
Heimburger, DC | 1 |
Nyirenda, CK | 1 |
Wellons, MF | 1 |
Bagchi, S | 1 |
Chi, BH | 1 |
Koethe, JR | 1 |
Arnett, DK | 1 |
Kabagambe, EK | 1 |
Fillekes, Q | 2 |
Mulenga, V | 1 |
Kabamba, D | 1 |
Kankasa, C | 3 |
Thomason, MJ | 2 |
Cook, A | 1 |
Chintu, C | 1 |
Gibb, DM | 2 |
Walker, AS | 2 |
Burger, DM | 2 |
Zheng, X | 1 |
Mueller, GA | 1 |
DeRose, EF | 1 |
London, RE | 1 |
Muro, EP | 1 |
Chunda, C | 1 |
Aitken, S | 1 |
Kisanga, ER | 1 |
Ramokolo, V | 1 |
Fadnes, LT | 1 |
Doherty, T | 1 |
Jackson, DJ | 1 |
Chhagan, M | 1 |
Van den Broeck, J | 1 |
Dickinson, L | 1 |
Chaponda, M | 1 |
Carr, DF | 1 |
van Oosterhout, JJ | 1 |
Kumwenda, J | 1 |
Lalloo, DG | 1 |
Pirmohamed, M | 1 |
Heyderman, RS | 1 |
Khoo, SH | 1 |
Mir, F | 1 |
Qamar, FN | 1 |
Baig-Ansari, N | 1 |
Abro, AG | 1 |
Abbas, SQ | 1 |
Kazi, MA | 1 |
Rizvi, A | 1 |
Zaidi, AK | 1 |
Munshi, SU | 1 |
Panda, H | 1 |
Holla, P | 1 |
Rewari, BB | 2 |
Jameel, S | 1 |
Boettiger, DC | 1 |
Kerr, S | 1 |
Ditangco, R | 1 |
Merati, TP | 1 |
Pham, TT | 1 |
Chaiwarith, R | 1 |
Kiertiburanakul, S | 1 |
Li, CK | 1 |
Kumarasamy, N | 3 |
Vonthanak, S | 1 |
Lee, C | 1 |
Van Kinh, N | 1 |
Pujari, S | 1 |
Wong, WW | 1 |
Kamarulzaman, A | 1 |
Zhang, F | 1 |
Yunihastuti, E | 1 |
Choi, JY | 1 |
Oka, S | 1 |
Ng, OT | 1 |
Kantipong, P | 1 |
Mustafa, M | 1 |
Ratanasuwan, W | 1 |
Sohn, A | 1 |
Law, M | 1 |
Mavura, DR | 1 |
Masenga, EJ | 1 |
Minja, E | 1 |
Grossmann, H | 1 |
Crump, JA | 1 |
Bartlett, JA | 1 |
Shearer, K | 1 |
Brennan, AT | 1 |
Maskew, M | 1 |
Long, L | 1 |
Berhanu, R | 1 |
Sanne, I | 1 |
Fox, MP | 1 |
Ramana, LN | 1 |
Sharma, S | 1 |
Sethuraman, S | 1 |
Ranga, U | 1 |
Krishnan, UM | 1 |
Palombi, L | 3 |
Galluzzo, CM | 1 |
Andreotti, M | 2 |
Liotta, G | 2 |
Jere, H | 1 |
Sagno, JB | 1 |
Luhanga, R | 1 |
Mancinelli, S | 1 |
Amici, R | 1 |
Marazzi, MC | 3 |
Vella, S | 2 |
Giuliano, M | 3 |
Lanzafame, M | 2 |
Lattuada, E | 2 |
Rigo, F | 1 |
Nicole, S | 1 |
Cucchetto, G | 1 |
Vento, S | 2 |
van Griensven, J | 1 |
Choun, K | 1 |
Chim, B | 1 |
Thai, S | 1 |
Lorent, N | 1 |
Lynen, L | 1 |
Dalvi, BR | 1 |
Siddiqui, EA | 1 |
Syed, AS | 1 |
Velhal, SM | 1 |
Ahmad, A | 1 |
Bandivdekar, AB | 1 |
Devarajan, PV | 1 |
Bolaris, MA | 1 |
Keller, MA | 1 |
Robbins, BL | 1 |
Podany, AT | 1 |
Fletcher, CV | 1 |
Olana, T | 1 |
Bacha, T | 1 |
Worku, W | 1 |
Tadesse, BT | 1 |
Gray, GE | 1 |
Saloojee, H | 1 |
Church, JD | 3 |
Omer, SB | 3 |
Guay, LA | 3 |
Huang, W | 2 |
Lidstrom, J | 1 |
Musoke, P | 3 |
Mmiro, F | 1 |
Jackson, JB | 3 |
Eshleman, SH | 3 |
Li, T | 1 |
Dai, Y | 1 |
Kuang, J | 1 |
Jiang, J | 1 |
Han, Y | 1 |
Qiu, Z | 1 |
Xie, J | 1 |
Zuo, L | 1 |
Li, Y | 1 |
Walter, J | 1 |
Semrau, K | 1 |
Sinkala, M | 1 |
Thea, DM | 1 |
Aldrovandi, GM | 1 |
Moorthy, A | 2 |
Gupta, A | 1 |
Bhosale, R | 1 |
Tripathy, S | 1 |
Sastry, J | 1 |
Kulkarni, S | 1 |
Thakar, M | 1 |
Bharadwaj, R | 1 |
Kagal, A | 1 |
Bhore, AV | 1 |
Patil, S | 1 |
Kulkarni, V | 1 |
Venkataramani, V | 1 |
Balasubramaniam, U | 1 |
Suryavanshi, N | 1 |
Ziemniak, C | 1 |
Gupte, N | 1 |
Bollinger, R | 1 |
Persaud, D | 2 |
Shipton, LK | 1 |
Wester, CW | 1 |
Stock, S | 1 |
Ndwapi, N | 1 |
Gaolathe, T | 1 |
Thior, I | 1 |
Avalos, A | 1 |
Moffat, HJ | 1 |
Mboya, JJ | 1 |
Widenfelt, E | 1 |
Essex, M | 1 |
Hughes, MD | 2 |
Shapiro, RL | 1 |
Ammann, AJ | 1 |
Mwatha, A | 2 |
Bagenda, D | 2 |
Donnell, D | 1 |
Nakabiito, C | 1 |
Eure, C | 2 |
Bakaki, P | 2 |
Matovu, F | 2 |
Thigpen, MC | 2 |
McConnell, M | 2 |
Zoppini, G | 1 |
Concia, E | 1 |
Parkin, N | 1 |
Marlowe, N | 1 |
Mwinga, K | 1 |
Vermund, SH | 1 |
Chen, YQ | 1 |
Read, JS | 1 |
Urassa, W | 1 |
Carpenetti, N | 1 |
Valentine, M | 1 |
Goldenberg, RL | 1 |
Jaffar, S | 1 |
Amuron, B | 1 |
Foster, S | 1 |
Birungi, J | 1 |
Levin, J | 1 |
Namara, G | 1 |
Nabiryo, C | 1 |
Ndembi, N | 1 |
Kyomuhangi, R | 1 |
Opio, A | 1 |
Bunnell, R | 1 |
Tappero, JW | 1 |
Mermin, J | 1 |
Coutinho, A | 1 |
Grosskurth, H | 1 |
Corbett, AH | 1 |
Hosseinipour, MC | 1 |
Nyirenda, J | 1 |
Kanyama, C | 1 |
Rezk, NL | 1 |
Mkupani, P | 1 |
Sichali, D | 1 |
Tien, H | 1 |
Kashuba, AD | 1 |
Mwansambo, C | 1 |
Weigel, R | 1 |
Kazembe, P | 1 |
Torpey, K | 1 |
Kasonde, P | 1 |
Dirks, R | 1 |
Bweupe, M | 1 |
Kabaso, M | 1 |
Mandala, J | 1 |
Sangiwa, G | 1 |
Beldjebel, I | 1 |
Vujcikova, J | 1 |
Sokolova, J | 1 |
Krcmery, V | 1 |
Manosuthi, W | 1 |
Tantanathip, P | 1 |
Chimsuntorn, S | 1 |
Eampokarap, B | 1 |
Thongyen, S | 1 |
Nilkamhang, S | 1 |
Sungkanuparph, S | 1 |
Bachani, D | 1 |
Rajasekaran, S | 1 |
Deshpande, A | 1 |
Chan, PL | 1 |
Srikantiah, P | 1 |
Cournil, A | 1 |
Coudray, M | 1 |
Kouanfack, C | 1 |
Essomba, CN | 1 |
Tonfack, CA | 1 |
Biwolé-Sida, M | 1 |
Delaporte, E | 1 |
Bork, K | 1 |
Laurent, C | 1 |
Nielsen-Saines, K | 1 |
Zhang, C | 1 |
Sun, Y | 1 |
Hong, C | 1 |
Xiang, K | 1 |
Guo, Y | 1 |
Bartlam, M | 1 |
Lou, Z | 1 |
Meyers, T | 1 |
Sherman, G | 1 |
Tsai, WY | 1 |
Chen, YH | 1 |
Dlamini, JN | 1 |
Hu, Z | 1 |
Somaroo, H | 1 |
Highbarger, HC | 1 |
Follmann, DA | 1 |
Dewar, RL | 1 |
Pau, AK | 1 |
Ukwe, CV | 1 |
Ekwunife, OI | 1 |
Udeogaranya, OP | 1 |
Iwuamadi, UI | 1 |
Pérez Pedrero, D | 1 |
Górgolas, M | 1 |
Fernández Guerrero, ML | 1 |
Bommenel, T | 1 |
Launay, O | 1 |
Meynard, JL | 1 |
Gilquin, J | 1 |
Katlama, C | 1 |
Lascaux, AS | 1 |
Mahamat, A | 1 |
Martinez, V | 1 |
Pradier, C | 1 |
Rouveix, E | 1 |
Simon, A | 1 |
Costagliola, D | 1 |
Abgrall, S | 1 |
Ellis, GM | 1 |
Huang, S | 1 |
Hitti, J | 2 |
Martins, AN | 1 |
Arruda, MB | 1 |
Aleixo, AW | 1 |
Pires, AF | 1 |
Greco, DB | 1 |
de M Brindeiro, R | 1 |
Tanuri, A | 1 |
Van Dyke, RB | 1 |
Ngo-Giang-Huong, N | 1 |
Shapiro, DE | 1 |
Frenkel, L | 1 |
Britto, P | 1 |
Roongpisuthipong, A | 1 |
Yuthavisuthi, P | 1 |
Prommas, S | 1 |
Puthanakit, T | 1 |
Achalapong, J | 1 |
Chotivanich, N | 1 |
Rasri, W | 1 |
Cressey, TR | 2 |
Maupin, R | 1 |
Mirochnick, M | 1 |
Jourdain, G | 1 |
Chokephaibulkit, K | 1 |
Capparelli, E | 1 |
Sirisanthana, V | 1 |
Muresan, P | 1 |
Hongsiriwon, S | 1 |
Ngampiyaskul, C | 1 |
Limwongse, C | 1 |
Wittawatmongkol, O | 1 |
Aurpibul, L | 1 |
Kabat, B | 1 |
Toye, M | 1 |
Smith, ME | 1 |
Eksaengsri, A | 1 |
McIntosh, K | 1 |
Yogev, R | 1 |
Pennings, PS | 1 |
Landolt, NK | 1 |
Phanuphak, N | 1 |
Ubolyam, S | 1 |
Pinyakorn, S | 1 |
Kriengsinyot, R | 1 |
Ahluwalia, J | 1 |
Thongpaeng, P | 1 |
Gorowara, M | 1 |
Thammajaruk, N | 1 |
Chaithongwongwatthana, S | 1 |
Lange, JM | 1 |
Ananworanich, J | 1 |
McMahon, DK | 1 |
Zheng, L | 1 |
Chan, ES | 1 |
Halvas, EK | 1 |
Hong, F | 1 |
Kabanda, J | 1 |
Taulo, F | 1 |
Bonhomme, J | 1 |
Wallis, CL | 1 |
Klingman, KL | 1 |
Mellors, JW | 1 |
Montaner, JS | 1 |
Cahn, P | 1 |
Zala, C | 1 |
Casssetti, LI | 1 |
Losso, M | 1 |
Hall, DB | 1 |
Wruck, J | 1 |
McDonough, M | 1 |
Gigliotti, M | 1 |
Robinson, PA | 1 |
Parienti, JJ | 1 |
Massari, V | 1 |
Descamps, D | 1 |
Vabret, A | 1 |
Bouvet, E | 1 |
Larouzé, B | 1 |
Verdon, R | 1 |
Tebas, P | 1 |
Yarasheski, K | 1 |
Henry, K | 2 |
Claxton, S | 1 |
Kane, E | 1 |
Bordenave, B | 1 |
Klebert, M | 1 |
Powderly, WG | 1 |
Check, E | 1 |
Sienz, M | 1 |
Zilly, M | 1 |
Ebigbo, A | 1 |
Knipper, A | 1 |
Winzer, R | 1 |
Klinker, H | 1 |
Langmann, P | 1 |
Goulder, PJ | 1 |
Blanckenberg, N | 1 |
Dong, K | 1 |
Gianotti, N | 1 |
Boeri, E | 1 |
Maillard, M | 1 |
Serra, G | 1 |
Ratti, D | 1 |
Gallotta, G | 1 |
Vacchini, D | 1 |
Tremolada, Y | 1 |
Castagna, A | 1 |
Dailly, E | 1 |
Tribut, O | 1 |
Tattevin, P | 1 |
Arvieux, C | 1 |
Perré, P | 1 |
Raffi, F | 1 |
Jolliet, P | 1 |
DeJesus, E | 1 |
Piliero, PJ | 1 |
Summers, K | 1 |
Wire, MB | 1 |
Stein, DS | 1 |
Masterman, A | 1 |
Lou, Y | 1 |
Min, SS | 1 |
Shelton, MJ | 1 |
Martinson, NA | 1 |
Gray, G | 1 |
Moodley, D | 1 |
Pillay, V | 1 |
Cohen, S | 1 |
Dhlamini, P | 1 |
Puren, A | 1 |
Bhayroo, S | 1 |
Steyn, J | 1 |
McIntyre, JA | 1 |
Guidotti, G | 1 |
Pirillo, MF | 1 |
Villani, P | 1 |
Mancini, MG | 1 |
Cusato, M | 1 |
Germano, P | 1 |
Loureiro, S | 1 |
Ceffa, S | 1 |
Regazzi, M | 1 |
Venkatesh, KK | 1 |
Devaleenal, B | 1 |
Palanivel, V | 1 |
Cecelia, AJ | 1 |
Muthu, S | 1 |
Yepthomi, T | 1 |
Mayer, KH | 1 |
Flanigan, T | 1 |
Shekelle, P | 1 |
Maglione, M | 1 |
Geotz, MB | 1 |
Wagner, G | 1 |
Hilton, L | 1 |
Carter, J | 1 |
Chen, S | 1 |
Tringle, C | 1 |
Mojica, W | 1 |
Newberry, S | 1 |
Mubiru, M | 1 |
Downing, R | 1 |
Greenberg, AE | 1 |
Toure, S | 1 |
Kouadio, B | 1 |
Seyler, C | 1 |
Traore, M | 1 |
Dakoury-Dogbo, N | 1 |
Duvignac, J | 1 |
Diakite, N | 1 |
Karcher, S | 1 |
Grundmann, C | 1 |
Marlink, R | 1 |
Dabis, F | 1 |
Anglaret, X | 1 |
Gozlan, M | 1 |
Connell, EV | 1 |
Hsu, MC | 1 |
Richman, DD | 4 |
Havlir, D | 1 |
McLaughlin, MM | 1 |
Rennie, J | 1 |
Cohen, J | 2 |
Nowak, MA | 1 |
Voelker, R | 1 |
Okamoto, M | 1 |
Makino, M | 1 |
Yamada, K | 1 |
Nakade, K | 1 |
Yuasa, S | 1 |
Erlander, SR | 1 |
Havlir, DV | 1 |
Eastman, S | 1 |
Gamst, A | 1 |
Collins, DO | 1 |
Sakamoto, A | 1 |
Miller, V | 1 |
Staszewski, S | 1 |
Boucher, CA | 1 |
Phair, JP | 1 |
Erice, A | 1 |
Balfour, HH | 1 |
Fischl, MA | 1 |
Kmack, A | 1 |
Liou, SH | 1 |
Kenton, A | 1 |
Hirsch, MS | 1 |
Phair, J | 1 |
Martinez, A | 1 |
Kahn, JO | 1 |
Titmuss, SJ | 1 |
Keller, PA | 1 |
Griffith, R | 1 |
Cherry, M | 2 |
Clarke, S | 1 |
Harrington, P | 1 |
Barry, M | 1 |
Mulcahy, F | 1 |
Gutiérrez, F | 1 |
Moltó, J | 1 |
Escolano, C | 1 |
Mora, A | 1 |
Pasquau, F | 1 |
Gregori, J | 1 |
Nogueira, E | 1 |
Casado, JL | 1 |
Dronda, F | 1 |
Sabido, R | 1 |
Antela, A | 1 |
Martí-Belda, P | 1 |
Dehertogh, P | 1 |
Moreno, S | 1 |
James, JS | 1 |
Bowers, M | 1 |
Mascolini, M | 1 |
Link, D | 1 |
Doepel, L | 1 |
Folkers, G | 1 |
Howorka, S | 1 |
Cheley, S | 1 |
Bayley, H | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Neuropsychiatric Adverse Effects of Efavirenz in Children Living With HIV in Kilimanjaro, Tanzania[NCT03227653] | 144 participants (Actual) | Observational | 2017-06-19 | Completed | |||
The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance After a Single Dose Nevirapine (VIramune®), Which is Part of ARV Prophylaxis for PMTCT in Moshi, TAnzania, and in Lusaka, Zambia (VITA2 Trial)[NCT01187719] | Phase 2 | 66 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
PROMISE EBF: Promoting Infant Health and Nutrition in Sub-Saharan Africa: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV[NCT00397150] | 2,579 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
[NCT00618176] | Phase 4 | 198 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
Short Duration Exclusive Breastfeeding With Abrupt Weaning to Reduce the Risk of Mother-to-Child HIV Transmission[NCT00310726] | 1,435 participants (Actual) | Interventional | 2001-05-31 | Completed | |||
Prevention of Maternal to Infant HIV Transmission in India[NCT00061321] | Phase 3 | 770 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission[NCT00021671] | Phase 3 | 3,720 participants | Interventional | Completed | |||
Short-term Effectiveness of a Community Health Worker Intervention for HIV-infected Pregnant Women in Tanzania to Improve Treatment Adherence and Retention in Care: A Cluster-Randomized Trial[NCT03058484] | 1,830 participants (Actual) | Interventional | 2015-05-01 | Completed | |||
Community ART for Retention in Zambia: Evaluating the Feasibility, Effectiveness, and Efficiency of Decentralized and Streamlined Antiretroviral Therapy Care Models[NCT02776254] | 3,100 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177] | Phase 4 | 96 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
[NCT00398684] | Phase 3 | 1,792 participants | Interventional | 2001-01-31 | Completed | ||
Phase II Study of the Pharmacokinetics of Nevirapine and the Incidence of Nevirapine Resistance Mutations in HIV-Infected Women Receiving a Single Intrapartum Dose of Nevirapine With the Concomitant Administration of Zidovudine/Didanosine or Zidovudine/Di[NCT00109590] | Phase 2 | 175 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine[NCT00099632] | Phase 2 | 484 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3[NCT00000747] | Phase 2 | 10 participants | Interventional | Completed | |||
A Randomized, Double-Blind, Three-Arm Study Comparing Combination to Monthly Alternating Nucleoside Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3) With a Prior History of Nucleoside Therapy[NCT00001029] | Phase 2 | 654 participants | Interventional | Completed | |||
A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)[NCT00000781] | Phase 2 | 1,292 participants | Interventional | Completed | |||
A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and Lamivudine (3TC) in Moderately Advanced HIV-1 Disease[NCT00001075] | 55 participants | Interventional | Completed | ||||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
Intervention | participants (Number) |
---|---|
Intervention | 310 |
No Intervention | 161 |
The EBF prevalences based on 24-h recall at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
Intervention | participants (Number) |
---|---|
Intervention | 56 |
No Intervention | 30 |
The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
Intervention | participants (Number) |
---|---|
Intervention | 323 |
No Intervention | 161 |
(NCT00397150)
Timeframe: at 3 months of age
Intervention | participants (Number) |
---|---|
Intervention | 104 |
No Intervention | 101 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
Intervention | ug*hr/mL (Median) |
---|---|
Within 72 Hrs Ppm | 99.7 |
At Day 30 Ppm | NA |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
Intervention | ug/mL (Median) |
---|---|
Within 72 Hrs Ppm | 10.78 |
At Day 30 Ppm | 12.96 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
Intervention | ug/mL (Median) |
---|---|
Within 72 Hrs Ppm | 11.2 |
At Day 30 Ppm | NA |
(NCT00109590)
Timeframe: at 24 weeks postpartum
Intervention | log10 copies/mL (Median) |
---|---|
Arm A : LPV/r x 7d | 4.3 |
Arm B : no LPV/r | 3.9 |
Arm C: LPV/r x 30d | 4.0 |
Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading > the Severity of Adult and Pediatric Adverse Events (December 2004). All grade 3 and higher signs, symptoms, and laboratory toxicities (and events of any grade that led to a change in study treatment) were included. (NCT00109590)
Timeframe: After start of study Treatment (postpartum)
Intervention | participants (Number) |
---|---|
Arm A : LPV/r x 7d | 2 |
Arm B : no LPV/r | 0 |
Arm C: LPV/r x 30d | 2 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
Intervention | ug/mL (Median) |
---|---|
Within 72 Hrs Ppm | 6.08 |
At Day 30 Ppm | 9.17 |
Resistance mutations as identified by consensus sequencing or OLA (NCT00109590)
Timeframe: 24 weeks postpartum
Intervention | participants (Number) |
---|---|
Arm B : no LPV/r | 0 |
Arm C: LPV/r x 30d | 0 |
The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.
Intervention | percent of participants (Number) |
---|---|
Arm A : LPV/r x 7d | 3.6 |
Arm B : no LPV/r | 7.1 |
Arm C : LPV/r x 30d | 5.3 |
The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.
Intervention | percent of participants (Number) |
---|---|
Arm A: LPV/r x 7d | 4.9 |
Arm B: no LPV/r | 9.5 |
Arm C : LPV/r x 30d | 7.0 |
The incidence of new NVP resistance mutation in plasma HIV within 8 weeks postpartum in each randomized arm was estimated using an exact binomial confidence interval. If a resistance mutation was detected at any of the timepoints then an endpoint was met. Samples with VL <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml (e.g.missed visit), it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: within 8 weeks postpartum.
Intervention | percent of participants (Number) |
---|---|
Arm A : LPV/r x 7d | 7.1 |
Arm B : no LPV/r | 12.5 |
Arm C: LPV/r x 30d | 5.3 |
Resistance mutations as identified by OLA in plasma samples or PBMC at 72 weeks postpartum amongst women who had new NVP resistance mutations within 8 weeks postpatrum. These results were based on the 13 women who developed a new NVP resistance mutation in the first 8 weeks postpartum. For the primary outcome measure 1, one particpant in arm A was unavailable for follow-up after week 5 and was conservatively imputed to have developed resistance mutation. (NCT00109590)
Timeframe: within 72 weeks postpartum
Intervention | participants (Number) | |
---|---|---|
OLA in plasma samples | OLA in PBMC | |
Arm A : LPV/r x 7d | 0 | 0 |
Arm B : no LPV/r | 0 | 0 |
Arm C: LPV/r x 30d | 0 | 1 |
(NCT00109590)
Timeframe: At Week 5 postpartum (ZDV) and at the first timepoint with viral load >=500 copies/ml after treatment discontinuation (ddI and LPV/r).
Intervention | percent of participants (Number) | ||
---|---|---|---|
The proportion of women with new ZDV resistance | The proportion of women with new ddI resistance | The proportion of women with new LPV/r resistance | |
Arm A : LPV/r x 7d | 0 | 0 | 0 |
Arm B : no LPV/r | 1.78 | 0 | 0 |
Arm C: LPV/r x 30d | 0 | 0 | 0 |
participants assigned to 7-day treatment arm and 21-day treatment arm were supposed to stay in study treatment for 7 days and 21 days respectively. (NCT00099632)
Timeframe: From first day of study treatment to last day of study treatment (up to 21 days)
Intervention | participants (Number) |
---|---|
7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
21-day Lamivudine/Zidovudine (3TC/ZDV) | 2 |
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
7-day Lopinavir/Ritonavir (LPV/r) | 0 |
21-day Lopinavir/Ritonavir (LPV/r) | 5 |
"For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed to the primary endpoint; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed to primary endpoint.~10 participants who did not have resistance samples available were excluded from the primary endpoint analysis." (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
Intervention | participants (Number) |
---|---|
7-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
21-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
7-day Lopinavir/Ritonavir (LPV/r) | 3 |
21-day Lopinavir/Ritonavir (LPV/r) | 1 |
For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
Intervention | participants (Number) |
---|---|
7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
21-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
7-day Lopinavir/Ritonavir (LPV/r) | 1 |
21-day Lopinavir/Ritonavir (LPV/r) | 0 |
For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
Intervention | participants (Number) |
---|---|
7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
21-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
7-day Lopinavir/Ritonavir (LPV/r) | 0 |
21-day Lopinavir/Ritonavir (LPV/r) | 0 |
"Grade 3 or higher signs and symptoms, laboratory abnormalities, events that are reported through the EAE system, and any grade event that leads to a treatment change from first day of study treatment to week 12.~Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death" (NCT00099632)
Timeframe: From first day of study treatment to week 12
Intervention | participants (Number) |
---|---|
7-day Lamivudine/Zidovudine (3TC/ZDV) | 5 |
21-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
7-day Lopinavir/Ritonavir (LPV/r) | 2 |
21-day Lopinavir/Ritonavir (LPV/r) | 2 |
7 reviews available for nevirapine and HIV
Article | Year |
---|---|
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Crystallography, X-Ray; Drug Design; | 2005 |
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
Topics: Anti-HIV Agents; Drug Discovery; HIV; HIV Fusion Inhibitors; HIV Infections; HIV Integrase; HIV Inte | 2015 |
Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies.
Topics: Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Drug Resistance, Viral; Female; HIV | 2009 |
Antiretroviral (ARV) drug resistance in the developing world.
Topics: Africa; Anti-HIV Agents; Asia; Child; Developing Countries; Drug Resistance, Viral; Female; HIV; HIV | 2007 |
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; H | 1994 |
AIDS pathogenesis: from models to viral dynamics in patients.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; HIV; HIV Infection | 1995 |
Clinical experience with non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Animals; Anti-HIV Agents; Delavirdine; HIV; HIV Infections; Nevirapine; N | 1997 |
23 trials available for nevirapine and HIV
Article | Year |
---|---|
Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Exanthema; Female; HIV; HIV Infections; Humans | 2013 |
Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.
Topics: Adult; Anti-HIV Agents; Anticonvulsants; Drug Interactions; Drug Resistance, Viral; Female; Half-Lif | 2013 |
Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Asian People; CD4 Lymphocyte | 2008 |
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
Topics: Anti-HIV Agents; Breast Feeding; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; Huma | 2009 |
Selected hematologic and biochemical measurements in African HIV-infected and uninfected pregnant women and their infants: the HIV Prevention Trials Network 024 protocol.
Topics: Adult; Anti-HIV Agents; Blood Cell Count; Double-Blind Method; Female; Follow-Up Studies; Gestationa | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
Topics: Adolescent; Anti-HIV Agents; Body Weight; Child; Child, Preschool; Cross-Over Studies; Dosage Forms; | 2010 |
Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia.
Topics: Anti-HIV Agents; Clinical Protocols; Developing Countries; Disease Transmission, Infectious; Drug Re | 2010 |
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies | 2011 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
Topics: Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Body Weig | 2011 |
Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptives, Oral, Synthetic; Cyclopro | 2013 |
Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; | 2013 |
Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
Topics: CD4 Lymphocyte Count; Drug Administration Schedule; Exanthema; Female; HIV; HIV Infections; Humans; | 2003 |
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Body Composition; Bone Density; C-Peptide; Cy | 2004 |
Follow-up measurements of Nevirapine plasma levels over a prolonged period.
Topics: Anti-HIV Agents; Body Weight; Drug Monitoring; Female; Follow-Up Studies; HIV; HIV Infections; Human | 2004 |
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; Furans; HIV; HIV Infections; HIV Prot | 2006 |
Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infectio | 2007 |
Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical | 2007 |
A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of > 500/mm3: AIDS Clinical Trials Group Protocol 208.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Female | 1995 |
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; H | 1994 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1998 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1998 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1998 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1998 |
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Topics: Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combinati | 2001 |
111 other studies available for nevirapine and HIV
Article | Year |
---|---|
5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
Topics: Animals; Antiviral Agents; Base Sequence; Biological Availability; HIV; HIV Reverse Transcriptase; H | 1993 |
Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
Topics: Anti-HIV Agents; Cell Line; Dideoxynucleotides; Dose-Response Relationship, Drug; HeLa Cells; HIV; H | 2007 |
Studies on anti-HIV quinolones: new insights on the C-6 position.
Topics: Anti-HIV Agents; HIV; Humans; Quinolones; Structure-Activity Relationship; Transcription, Genetic; V | 2009 |
New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Cell Survival; Cell Transformation, Viral; Computer Simul | 2009 |
Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
Topics: Anti-HIV Agents; Cell Line; HIV; HIV Reverse Transcriptase; Humans; Inhibitory Concentration 50; Iod | 2009 |
"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
Topics: Anti-HIV Agents; Antiviral Agents; Cell Line; Dendrimers; HIV; Humans; Static Electricity; Structure | 2010 |
Anti-HIV and antiplasmodial activity of original flavonoid derivatives.
Topics: Anti-HIV Agents; Antimalarials; Cell Line; Cell Survival; Flavonoids; HIV; HIV Infections; Humans; M | 2010 |
Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Cell Line; HIV; HIV Infections; HIV Reverse Transcriptase; I | 2011 |
Asymmetric total synthesis of (+)- and (-)-clusianone and (+)- and (-)-clusianone methyl enol ether via ACC alkylation and evaluation of their anti-HIV activity.
Topics: Alkylation; Anti-HIV Agents; Benzophenones; Benzoquinones; Bridged Bicyclo Compounds; Cell Line; Eth | 2011 |
Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; Heterocyclic Compounds; HIV; HIV Rev | 2014 |
Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands.
Topics: Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; HIV; Humans; Ligands; Microbial Sensit | 2014 |
Novel indole based NNRTIs with improved potency against wild type and resistant HIV.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; HIV; HIV Reverse Transcriptase; Indoles; Microbia | 2014 |
Semi-synthesis of oxygenated dolabellane diterpenes with highly in vitro anti-HIV-1 activity.
Topics: Anti-HIV Agents; Cell Line, Transformed; Diterpenes; Dose-Response Relationship, Drug; HIV; Humans; | 2014 |
Dithiocarbamate-thiourea hybrids useful as vaginal microbicides also show reverse transcriptase inhibition: design, synthesis, docking and pharmacokinetic studies.
Topics: Anti-Infective Agents; Female; HeLa Cells; HIV; Humans; Microbial Sensitivity Tests; Molecular Docki | 2015 |
Antiretroviral (HIV-1) activity of azulene derivatives.
Topics: Anti-HIV Agents; Azulenes; Cell Line; Cell Survival; Dose-Response Relationship, Drug; HIV; Humans; | 2016 |
Application of the Huisgen cycloaddition and 'click' reaction toward various 1,2,3-triazoles as HIV non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Click Chemistry; Cyclization; Dose-Response Relationship, Drug; HIV; HIV Reverse Tr | 2016 |
Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Carboxylic Acids; DNA-Directed RNA Polymerases; Dose-Respons | 2016 |
Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Reverse Transcriptase; Huma | 2020 |
Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
Topics: Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Reverse T | 2021 |
Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants.
Topics: Anti-HIV Agents; Breast Feeding; Case-Control Studies; Drug Resistance; Female; HIV; HIV Infections; | 2022 |
Cutaneous adverse drug reactions among people living with human immunodeficiency virus in a tertiary care hospital in Johor, Malaysia.
Topics: Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infection | 2022 |
Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Female; Follow-Up Studi | 2019 |
Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by
Topics: Artemether; Artemether, Lumefantrine Drug Combination; Cytochrome P-450 CYP2B6; Genotype; HIV; Nevir | 2020 |
Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys.
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Eswatini; Female; | 2020 |
LC-MS/MS Quantification of Nevirapine and Its Metabolites in Hair for Assessing Long-Term Adherence.
Topics: Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Female; Hair; HIV; HIV Infections; Humans; Mal | 2020 |
HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies; | 2021 |
Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; HIV; Humans; Nevirapine; Patch Tests; Pr | 2017 |
Safety Evaluation of Efavirenz in Children: Don't Forget the Central Nervous System.
Topics: Alkynes; Benzoxazines; Child; Cyclopropanes; HIV; Humans; Lopinavir; Nervous System; Nevirapine; Rit | 2018 |
Reply to Van de Wijer et al.
Topics: Alkynes; Benzoxazines; Child; Cyclopropanes; HIV; Humans; Lopinavir; Nevirapine; Ritonavir | 2018 |
HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induce | 2018 |
Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure.
Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistanc | 2020 |
Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2018 |
Programmes for the prevention of mother-to-child HIV infection transmission have made progress in Yunnan Province, China, from 2006 to 2015: a cost effective and cost-benefit evaluation.
Topics: Adult; China; Cost-Benefit Analysis; Delivery of Health Care; Female; Health Expenditures; HIV; HIV | 2019 |
Changes in Lipid Indices in HIV+ Cases on HAART.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Dia | 2019 |
Incidence, prevalence and associated factors of mother-to-child transmission of HIV, among children exposed to maternal HIV, in Belgaum district, Karnataka, India.
Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Breast Feeding; Child, Preschool; Female; HIV; HIV | 2019 |
Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV; HIV Infecti | 2019 |
Retention of HIV exposed infants in care at Arua regional referral hospital, Uganda: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Chi-Square Distribution; Female; HIV; HIV Infections; Humans; Infant, Newbor | 2019 |
Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; Cohort Studies; Cyclopropanes; Female | 2019 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxa | 2013 |
Protein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Anti-HIV Agents; HIV; HIV Reverse Transcriptase; Kineti | 2013 |
HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants.
Topics: Adolescent; Adult; Anti-HIV Agents; Black People; Female; Growth Disorders; HIV; HIV Infections; HIV | 2014 |
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Biotransformation; Black People; Cytochrome P | 2014 |
Clinical manifestations and treatment outcomes in HIV-1-infected children receiving antiretroviral therapy in Karachi, Pakistan.
Topics: Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Child, Preschool; Drug Resistance, | 2014 |
MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazi | 2014 |
Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asia; Dideoxynucleosides; Drug-Relate | 2014 |
Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; | 2015 |
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies; | 2014 |
Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Antigens; Drug Carriers; HEK293 Cells; H | 2015 |
Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; | 2015 |
Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV; HI | 2015 |
Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Cambodia; Drug Interactio | 2015 |
Nevirapine Loaded Core Shell Gold Nanoparticles by Double Emulsion Solvent Evaporation: In vitro and In vivo Evaluation.
Topics: Animals; Anti-HIV Agents; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Emulsions | 2016 |
Nevirapine Plasma Concentrations in Human Immunodeficiency Virus-Exposed Neonates Receiving High-Dose Nevirapine Prophylaxis as Part of 3-Drug Regimen.
Topics: Adult; Anti-Retroviral Agents; Drug Therapy, Combination; False Positive Reactions; Female; HIV; HIV | 2017 |
Early infant diagnosis of HIV infection using DNA-PCR at a referral center: an 8 years retrospective analysis.
Topics: Anti-HIV Agents; DNA, Viral; Early Diagnosis; Ethiopia; Female; HIV; HIV Infections; Humans; Infant; | 2016 |
Breast-feeding, antiretroviral prophylaxis, and HIV.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV; HIV Infections; Humans; Infant; Infectious Disease Tra | 2008 |
Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Infec | 2008 |
Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV; HIV Infections; Humans; I | 2008 |
Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; CD4 Lymphocyte Count; Comorbidity; Cyclopro | 2009 |
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Administration Schedule; Drug | 2009 |
No influence of nevirapine on vitamin D deficiency in HIV-infected patients.
Topics: Anti-HIV Agents; HIV; HIV Infections; Humans; Longitudinal Studies; Nevirapine; Vitamin D Deficiency | 2009 |
Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants.
Topics: Age Factors; Drug Resistance, Viral; HIV; HIV Infections; Humans; Infant; Mutation; Nevirapine; Reag | 2009 |
Predictors of treatment failure in Cambodian children with human immunodeficiency virus infection.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; Child; Child, Preschoo | 2010 |
Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte Count; Confide | 2010 |
Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV; HIV | 2010 |
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV; HIV In | 2010 |
Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte C | 2011 |
A novel non-radioactive assay for HIV-RT (RdDp) based on pyrosequencing for high-throughput drug screening.
Topics: Anti-HIV Agents; Colorimetry; Diphosphates; Drug Evaluation, Preclinical; HIV; HIV Reverse Transcrip | 2010 |
Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children.
Topics: Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Resistance, Viral; Female; Genotype; H | 2011 |
Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cli | 2011 |
Self-reported adherence to HAART in South-Eastern Nigeria is related to patients' use of pill box.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Algorithms; Anti-HIV Agents; Antiretrov | 2010 |
Nevirapine-induced agranulocytosis.
Topics: Agranulocytosis; Anti-HIV Agents; HIV; HIV Seropositivity; Humans; Male; Middle Aged; Nevirapine | 2011 |
Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; HIV Inf | 2011 |
Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cyclopropanes | 2011 |
Standing genetic variation and the evolution of drug resistance in HIV.
Topics: Anti-HIV Agents; Computational Biology; Computer Simulation; Drug Resistance, Viral; Evolution, Mole | 2012 |
Resistant HIV in breast milk.
Topics: Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Milk, Human; Nevirapine; Pregnancy | 2003 |
Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopro | 2004 |
Health minister ignites row over drugs for HIV mothers.
Topics: Congresses as Topic; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; I | 2004 |
Nevirapine plus zidovudine to prevent mother-to-child transmission of HIV.
Topics: Anti-Retroviral Agents; DNA, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; Infectious | 2004 |
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; | 2004 |
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cy | 2006 |
Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV; HIV Infections | 2007 |
Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda.
Topics: Anti-HIV Agents; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; HIV; HIV Infections; Humans; | 2007 |
Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'I | 2008 |
Update on HIV transmission and pathogenesis.
Topics: Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; Disease Models, Animal; Genes, env; HIV; HIV | 1995 |
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
Topics: Antiviral Agents; Benzodiazepines; Didanosine; Drug Synergism; Gene Products, tat; HeLa Cells; HIV; | 1994 |
Triple whammy. Will an AIDS therapy live up to its advance billing?
Topics: Acquired Immunodeficiency Syndrome; Cells, Cultured; Didanosine; Drug Therapy, Combination; HIV; Hum | 1993 |
AIDS drugs. Harvard group makes a splash--twice.
Topics: Antiviral Agents; Didanosine; HIV; Mutation; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors | 1993 |
Resisting the temptation.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Com | 1993 |
High turnover of HIV in blood revealed by new studies.
Topics: Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; HIV; HIV Infections; HIV Proteas | 1995 |
New HIV drugs cast in supporting roles.
Topics: Antiviral Agents; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Reverse Transcriptase Inhibito | 1996 |
Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells.
Topics: Acetamides; Acetophenones; Cell Line, Transformed; HIV; HIV Core Protein p24; HIV-1; Humans; Nevirap | 1996 |
The eighth mystery of acquired immune deficiency syndrome and the "Trojan horse' mechanism.
Topics: Acquired Immunodeficiency Syndrome; Apoptosis; CD4-Positive T-Lymphocytes; Endopeptidases; Eosinophi | 1996 |
Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Resistance, Microbial; HeLa Cells; HIV; HIV Infe | 1996 |
[Nevirapine: a new principle of action against HIV].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Do | 1996 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Th | 1997 |
Docking experiments in the flexible non-nucleoside inhibitor binding pocket of HIV-1 reverse transcriptase.
Topics: Binding Sites; Databases, Factual; HIV; HIV Reverse Transcriptase; Ligands; Molecular Structure; Nev | 1999 |
Mbeki gives AIDS scientists the cold shoulder.
Topics: Acquired Immunodeficiency Syndrome; Adult; Breast Feeding; Enzyme-Linked Immunosorbent Assay; Female | 2000 |
Diplomatic Mandela calls for action on HIV...as South Africa considers its options after free drugs offer.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Child; Drug Costs; Drug Industry; Female | 2000 |
The tolerability of efavirenz after nevirapine-related adverse events.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Anxiety Disorders; Benzoxazines; Cyclopropanes; Female; HIV; | 2000 |
[Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy].
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Microbial; End | 2000 |
New information on HIV rapid turnover--what does it mean?
Topics: Antiviral Agents; CD4 Lymphocyte Count; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indina | 1995 |
Non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Antiviral Agents; Delavirdine; Drug Approval; Drug Resistance, Microbial; | 1996 |
FDA approves first new class of HIV drugs. Food and Drug Administration.
Topics: Antiviral Agents; Drug Approval; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibi | 1996 |
Nevirapine: new drug, new class, new questions.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Approval; Drug Therapy, Combi | 1996 |
New York ADAP to cover new AIDS drugs plus viral load testing.
Topics: Acquired Immunodeficiency Syndrome; Antibiotics, Antineoplastic; Antiviral Agents; Cytomegalovirus I | 1996 |
Nevirapine--first of a new class of drugs.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV | 1996 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as To | 1997 |
Scientific basis for PEP rests in animal trials.
Topics: Adenine; Animals; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Health Personne | 1997 |
[Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; HIV; HIV Infections | 2001 |
Sequence-specific detection of individual DNA strands using engineered nanopores.
Topics: Base Pair Mismatch; Biosensing Techniques; Biotechnology; Cell Membrane; DNA; HIV; Lipid Bilayers; M | 2001 |
Nevirapine (Viramune).
Topics: Drug Resistance, Microbial; HIV; HIV Infections; Humans; Nevirapine; Practice Guidelines as Topic; R | 2000 |